首页> 外文期刊>Journal of cardiovascular electrophysiology >Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.
【24h】

Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.

机译:具有可进行心脏再同步治疗的植入式除颤器的患者中,适当除颤器治疗的预测指标。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

INTRODUCTION: The purpose of this study was to determine predictors of appropriate implantable defibrillator (ICD) therapy among patients with heart failure who are treated with a cardiac resynchronization therapy-defibrillator (CRT-D). METHODS AND RESULTS: Patients enrolled in the Ventak CHF/Contak CD study were treated with a CRT-D device and were required to have NYHA class II-IV CHF, QRS duration > or = 120 msec, and a class I or II indication for an ICD. The study database was retrospectively analyzed during the 6-month postimplant period to identify predictors of appropriate ICD therapy. Five hundred and one of the 581 patients enrolled in the trial had successful device implantation and were included in this analysis. Patients were mostly male (83%), 66 +/- 11 years old, and had coronary artery disease (69%), a mean left ventricular ejection fraction (EF) = 0.22 +/- 0.07, and NYHA class II (33%), III (58%), or IV (9%) CHF symptoms. During 6 months of follow-up, 73 of 501 (14%) patients received an appropriate ICD therapy. Two independent predictors of appropriate therapy were identified: a history of a spontaneous, sustained ventricular arrhythmia (HR = 2.05; 95% CI = 1.31-3.20; P = 0.002) and NYHA class IV CHF (HR = 1.81; 95% CI = 1.10-2.96; P = 0.019). When patients with NYHA class II were excluded from analysis, a history of a sustained ventricular arrhythmia and the presence of NYHA class IV CHF symptoms remained as independent predictors of appropriate ICD therapy. CONCLUSIONS: In a select population of advanced heart failure patients receiving a CRT-D, NYHA class IV CHF was a powerful independent predictor of appropriate ICD therapy. Approximately one-quarter of the patients with NYHA class IV CHF who received a CRT-D device received an appropriate ICD therapy within 3 months after implant. Additional studies are needed to confirm an association between class IV CHF symptoms and an increased frequency of ICD shocks.
机译:简介:这项研究的目的是确定在接受心脏再同步治疗除颤器(CRT-D)治疗的心力衰竭患者中,适当的植入式除颤器(ICD)治疗的预测指标。方法和结果:Ventak CHF / Contak CD研究的患者接受了CRT-D装置治疗,并要求其具有NYHA II-IV级CHF,QRS持续时间>或= 120毫秒,以及I级或II级适应症ICD。在植入后的6个月内对研究数据库进行回顾性分析,以确定合适的ICD治疗的预测指标。参与该试验的581例患者中有501例成功植入了设备,并纳入了该分析。患者多为男性(83%),66 +/- 11岁,患有冠状动脉疾病(69%),平均左心室射血分数(EF)= 0.22 +/- 0.07和NYHA II类(33%) ),III(58%)或IV(9%)CHF症状。在6个月的随访期间,501名患者中的73名(14%)接受了适当的ICD治疗。确定了两个独立的适当治疗预测因素:自发性持续性心律失常的病史(HR = 2.05; 95%CI = 1.31-3.20; P = 0.002)和NYHA IV级CHF(HR = 1.81; 95%CI = 1.10) -2.96; P = 0.019)。当将NYHA II类患者排除在分析范围之外时,持续性室性心律不齐的病史和NYHA IV类CHF症状的存在仍然是适当ICD治疗的独立预测指标。结论:在接受CRT-D治疗的部分晚期心力衰竭患者中,NYHA IV级CHF是适当ICD治疗的有力独立预测因子。植入CRT-D装置的NYHA IV级CHF患者中,约有四分之一在植入后3个月内接受了适当的ICD治疗。需要进行进一步的研究以确认IV级CHF症状与ICD休克频率增加之间的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号